罗沙司他治疗肾性贫血的效果观察及对TSAT、Cys C及NOX2的作用分析

摘要 目的：探讨罗沙司他治疗肾性贫血的效果观察及对转铁蛋白饱和度（TSAT）、胱抑素C（Cys C）及NADPH氧化酶2（NOX2）的作用。方法：选择2019年12月到2020年12月在我院接受治疗的125例肾性贫血患者，采用随机数表法分为试验组（n=63）和对照组（n=62）。对照组给予重组人促红素治疗，试验组给予罗沙司他治疗。比较两组临床疗效、TSAT、Cys C、NOX2、红细胞计数（RBC）、血红蛋白（Hb）、血细胞比容（Hct）、铁蛋白（SF）、转铁蛋白（TRF）及铁调素（Hepc）水平变化情况及药物不良反应发生情况。结果：治疗后，两组总有效率比较差异显著（P<0.05）；治疗前，试验组和对照组血清TSAT、Cys C及NOX2比较无显著差异；治疗后，试验组和对照组血清TSAT随着时间的推移而升高，且试验组高于对照组，Cys C及NOX2随着时间的推移而升减降低，且试验组低于对照组，差异显著（P<0.05）；治疗前，试验组和对照组RBC、Hb、Hct检验结果比较无显著差异；治疗后，试验组和对照组RBC、Hb、Hct均随着时间的推移而升高，且试验组高于对照组，差异显著（P<0.05）；治疗前，试验组和对照组SF、TRF及Hepc检验结果比较无显著差异；治疗后，试验组和对照组血清SF、TRF均随着时间的推移而升高，且试验组高于对照组，Hepc随着时间的推移而下降，且试验组低于对照组，差异显著（P<0.05）；两组不良反应总发生率分别为4.76%、8.06%（P>0.05）。结论：在肾性贫血患者中应用罗沙司他效果显著，可能与其可有效改善血清TSAT、Cys C及NOX2水平有关，且不增加不良反应。

Curative Efficacy of Observation on the Effect of Roxathat on Renal Anemia and Its Effect on TSAT, Cys C and NOX2

ABSTRACT Objective: To study Curative efficacy of Observation on the effect of roxathat on renal anemia and its effect on Transferrin saturation (TSAT), cystatin C (Cys C) and NADPH oxidase 2 (NOX2). Methods: 125 patients with renal anemia treated in our hospital from December 2019 to December 2020 were selected and divided into experimental group (n=63) and control group (n=62) by random number table method. The control group was treated with recombinant human erythropoietin and the experimental group was treated with roxathat. Clinical efficacy, TSAT, Cys C, NOX2, erythrocyte count(RBC), hemoglobin (Hb), hematocrit (HCT), ferritin (SF), transferrin (TRF) and ferritin (HEPC) levels and the incidence of adverse drug reactions were compared between the two groups. Results: After treatment, the total effective rate between the two groups was significantly different(P<0.05). Before treatment, there were no significant differences in serum TSAT, Cys C and NOX2 between the experimental group and the control group. After treatment, serum TSAT in experimental group and control group increased over time, and Cys C and Nox2 in experimental group increased and decreased over time, and the difference was significant(P<0.05). Before treatment, there were no significant differences in RBC, HB and HCT test results between the experimental group and the control group. After treatment, RBC, Hb and Hct in experimental group and control group increased with the passage of time, and the difference in experimental group was significant(P<0.05). Before treatment, there were no significant differences in SF, TRF and HEPC test results between the experimental group and the control group. After treatment, serum SF and TRF of both experimental group and control group increased with time, and the experimental group was higher than the control group, and the HEPC decreased with time, and the experimental group was lower than the control group, the difference was significant(P<0.05). The total incidence of ADR in the two groups was 4.76% and 8.06%(P>0.05), respectively. Conclusion: The application of roxathat in patients with renal anemia has a significant effect, which may be related to the effective improvement of serum TSAT, Cys C and NOX2 levels without increasing adverse reactions.